NYSE American to delist Calidi Biotherapeutics warrants due to low trading price

Calidi Biotherapeutics, Inc.

NYSE Regulation commences delisting of Calidi warrants (CLDI WS) under Section 1001 of NYSE American Company Guide.
Each warrant exercisable for 1/10th of a share at $115.00 per whole share; trading suspended immediately.
Company has right to appeal to Listings Qualifications Panel; common stock (CLDI) remains listed on NYSE American.
Delisting does not affect business operations or SEC reporting obligations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.